| Code | Description | Claims | Beneficiaries | Total Paid |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
4,964 |
4,916 |
$672K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,892 |
4,609 |
$453K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,946 |
2,915 |
$270K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,889 |
2,751 |
$195K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,684 |
1,633 |
$65K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
531 |
514 |
$26K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,516 |
1,490 |
$22K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,341 |
741 |
$20K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
693 |
607 |
$11K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
149 |
147 |
$5K |
| 87428 |
|
59 |
59 |
$4K |
| 81002 |
|
1,133 |
1,092 |
$3K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
12 |
12 |
$1K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
29 |
28 |
$933.38 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
60 |
60 |
$559.21 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
154 |
148 |
$240.59 |
| 36415 |
Collection of venous blood by venipuncture |
58 |
57 |
$149.37 |
| 99000 |
|
2,409 |
2,312 |
$47.53 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
46 |
46 |
$3.37 |